A Multicenter Prospective Cohort Study of FLOR3 Gene Polymorphism in Predicting Outcomes of TKI-stopping in Chronic Myeloid Leukemia
试验速览
- 阶段
- 不适用
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- treatment-free remission or relapse
研究概览
简要总结
For patients with chronic myeloid leukemia in chronic phase (CML-CP) who have achieved a stable deep molecular response (DMR) using BCR-ABL1 tyrosine kinase inhibitors (TKIs), treatment-free remission (TFR) following TKI cessation is an emerging goal. However, about half of the patients relapsed after TKI discontinuation. There is no definite examinations to predict the outcome of TKI discontinuation. Investigators aim to study the relationship between FLOR3 SNP rs139130389 and the outcome of TKI discontinuation.
详细描述
Investigators aim to detect FOLR3 SNP rs139130389, and establish its correlation with patients' treatment response, remission time, TKI resistance and the outcome of TKI stopping.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The patient signs the informed consent form
- •Age over 18, male or female
- •The patient was diagnosed as chronic phase of CML.
- •ECoG score 0-2
- •Receive TKI treatment for at least 4 years and continuously obtain MR4 or mr4.5 for at least 3 years.
- •The subjects fully understand and comply with the requirements of the research scheme and are willing to complete the research as planned.
排除标准
- 未提供
结局指标
主要结局
treatment-free remission or relapse
时间窗: 1 year
Observe whether the patients were in remission or relapse 1 year after drug withdrawal
次要结局
未报告次要终点